A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
To evaluate the safety of administering 1 or 2 doses of the quadrivalent influenza virus split vaccine (MDCK cells) (0.5ml/dose) in individuals aged 6 months and above.
Epistemonikos ID: ef0fb497e329da8c2752483141b0ef5d45dfa510
First added on: May 15, 2024